Bono Silvia, Dello Sbarba Persio, Lulli Matteo
Department of Experimental and Clinical Biomedical Sciences "Mario Serio" of Università degli Studi di Firenze and Istituto Toscano Tumori, Florence, Italy.
Data Brief. 2018 Sep 19;20:1901-1904. doi: 10.1016/j.dib.2018.09.041. eCollection 2018 Oct.
The data presented here are related to the original research article entitled "Imatinib enhances the maintenance of Chronic Myeloid Leukemia (CML) stem cell potential in the absence of glucose" (Bono et al., 2018). The sensitivity to the tyrosine kinase inhibitor imatinib-mesylate (IM) of KCL22 CML cells cultured under glucose shortage have been determined by scoring cell survival/growth via trypan blue exclusion and stem cell potential via Culture Repopulation Ability (CRA) assay. Discussion of the data can be found in Bono et al. (2018).
此处呈现的数据与原研究文章《伊马替尼在无糖条件下增强慢性粒细胞白血病（CML）干细胞潜能》（博诺等人，2018年）相关。通过台盼蓝排斥法对细胞存活/生长进行评分，并通过培养再增殖能力（CRA）测定法对干细胞潜能进行评估，从而确定了在葡萄糖缺乏条件下培养的KCL22 CML细胞对酪氨酸激酶抑制剂甲磺酸伊马替尼（IM）的敏感性。有关数据的讨论可在博诺等人（2018年）的文章中找到。
